Which antipsychotics should we consider selecting as the first-line and second-line treatments, and what should we base this decision on? Dr. Aziz addresses this in a past article from The Carlat Psychiatry Report. Here’s some of his advice:Process: Tolerability instead of efficacy should be considered when selecting a first-line treatment.
Rehan Aziz, MD.
Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School.
Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.